Bioreliance Ltd.December 5, 2025

FDA 483 - Bioreliance Ltd. - December 05, 2025

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Bioreliance Ltd.

Record Details

Bioreliance Ltd. in Glasgow, a drug substance manufacturer, received a Form 483 citing three significant observations. The firm failed to adequately investigate out-of-specification bioburden test results for an Adenovirus Type 7 batch, which was released to the U.S. market. Additionally, deficiencies were noted in material storage, inventory control, and aseptic practices during bulk filling operations.

Company: Bioreliance Ltd.
Inspection Date: December 5, 2025
Product Type: Drugs
Office: Office of Inspections and Investigations
People: Travis S. Bradley
Lewis K. Antwi

Open in Dashboard

ID · c87e74bb-34fe-4329-aab5-9c578962c664